Globally, 1.7m new cases of breast cancer are diagnosed each year, with 522,000 deaths. Breast cancer is the most frequent cause of cancer death in women in less developed regions,and is now the second cause of cancer death in more developed regions after lung cancer.
Sentimag® and Sienna+® were initially developed for staging breast cancer. The system was developed in the clinic, with surgeons providing vital feedback during the design and prototyping. The resulting procedure involves injecting Sienna+® into the sub-areolar region of the breast. Depending on the patient’s age, weight and breast size, the average time for Sienna+® to produce a detectable signal in the sentinel lymph nodes is 20 minutes. This compares favourably to the competition as injections can be made near or in the operating theatre and following anaesthesia, improving patient comfort and convenience.
Since its launch in late 2012, the system has produced a strong base of clinical results confirming its safety and efficacy. Multiple clinical studies and trials with over 1,500 patients across 12 European countries have completed, and all have demonstrated clinical equivalence to the standard of care for SLNB – either Technetium (99mTc) alone or the combination technique (99mTc and blue dye). For the latest results, see our Clinical section of the website for details.
